This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Bausch (BHC) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Bausch (BHC) Might be Well Poised for a Surge
by Zacks Equity Research
Bausch (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Moving Average Crossover Alert: Bausch Health Companies
by Zacks Equity Research
Bausch Health Companies is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Top Ranked Value Stocks to Buy for November 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 26th
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Generic Drugs Industry Turns the Corner on Price Stabilization
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs are leading to recovery in the industry. New launches are also a boost. However, competition remains stiff.
Will Bausch Health Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Bausch Health.
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bausch (BHC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.
Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 12.26% and 2.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Bausch Health (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
by Zacks Equity Research
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
by Zacks Equity Research
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
Foamix Initiates Phase II Study on Acne Combination Foam
by Zacks Equity Research
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
by Zacks Equity Research
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Why Is Bausch (BHC) Down 4.7% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study
by Zacks Equity Research
Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.
Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BHC) Outperforming Other Medical Stocks This Year?
Is Bausch Health Cos (BHC) a Good Value Investor Pick?
by Zacks Equity Research
Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.